

Insulin Secretion and Action in Subjects With Impaired Fasting Glucose and Impaired Glucose Tolerance

Results From the Veterans Administration Genetic Epidemiology Study

Muhammad A. Abdul-Ghani, Christopher P. Jenkinson, Dawn K. Richardson, Devjit Tripathy, and Ralph A. DeFronzo

This study was conducted to observe changes in insulin secretion and insulin action in subjects with impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT). A total of 319 subjects were studied with an oral glucose tolerance test (OGTT). Fasting plasma glucose and insulin concentrations were measured at baseline and every 30 min during the OGTT. Fifty-eight subjects also received a euglycemic-hyperinsulinemic clamp. Insulin sensitivity was calculated as the total glucose disposal (TGD) during the last 30 min of the clamp. Homeostasis model assessment of insulin resistance (HOMA-IR) was calculated from fasting plasma glucose and insulin concentrations. Subjects with IFG had TGD similar to normal glucose-tolerant subjects, while subjects with IGT and combined IFG/IGT had significantly reduced TGD. HOMA-IR in subjects with IFG was similar to that in subjects with combined IFG/IGT and significantly higher than HOMA-IR in subjects with IGT or NGT. Insulin secretion, measured by the insulinogenic index ($\Delta I_{0-30}/\Delta G_{0-30}$) and by the ratio of the incremental area under the curve (AUC) of insulin to the incremental AUC of glucose (0–120 min), was reduced to the same extent in all three glucose-intolerant groups. When both measurements of β -cell function were adjusted for severity of insulin resistance, subjects with IGT and combined IFG/IGT had a significantly greater reduction in insulin secretion than subjects with IFG. Subjects with IGT and IFG have different metabolic characteristics. Differences in insulin sensitivity and insulin secretion may predict different rates of progression to type 2 diabetes and varying susceptibility to cardiovascular disease. *Diabetes* 55:1430–1435, 2006

From the Diabetes Division, University of Texas Health Science Center, San Antonio, Texas.

Address correspondence and reprint requests to Ralph A. DeFronzo, Diabetes Division, University of Texas Health Science Center, 7703 Floyd Curl Dr., San Antonio, TX 78229. E-mail: albarado@uthscsa.edu.

Received for publication 12 September 2005 and accepted in revised form 13 February 2006.

AUC, area under the curve; CGI, combined glucose intolerance; EGP, endogenous glucose production; FPI, fasting plasma insulin; IFG, impaired fasting glucose; HGP, hepatic glucose production; HOMA-IR, homeostasis model assessment of insulin resistance; IGT, impaired glucose tolerance; NGT, normal glucose tolerance; OGIS, oral glucose insulin sensitivity; OGTT, oral glucose tolerance test; TGD, total glucose disposal.

DOI: 10.2337/db05-1200

© 2006 by the American Diabetes Association.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Impaired glucose intolerance (IGT) is an intermediate state in the transition from normal glucose tolerance (NGT) to type 2 diabetes (1). Subjects with IGT, although still normoglycemic, manifest the dual defects that are characteristic of type 2 diabetes: reduced insulin sensitivity and impaired β -cell function (2). As a result, they are at high risk for progression to type 2 diabetes, with an annual conversion rate of 5–10%, depending upon the ethnic group that is studied (3–7).

In 1997, the American Diabetes Association introduced another intermediate state, impaired fasting glucose (IFG) (8), in the transition of glucose homeostasis from NGT to type 2 diabetes. IFG was meant to be analogous to IGT, since subjects with IFG also are at high risk for progression to type 2 diabetes. In epidemiological studies (3–7), subjects with isolated IGT and isolated IFG had similar risk for progression to type 2 diabetes. However, only 45% of subjects with IFG had IGT; conversely, <25% of subjects with IGT had IFG (4,5,9–13). The partial overlap between IFG and IGT suggests that different pathophysiological mechanisms contribute to the disturbances in glucose homeostasis. In some studies, insulin resistance was reported to be the primary abnormality in subjects with IFG, while IGT was more associated with impaired β -cell function (14–21). However, other investigators have reported completely opposite results (22–26). In part, the divergent results may be explained by the failure to utilize more sophisticated techniques to quantitate insulin sensitivity and insulin secretion. In this study, we used the oral glucose tolerance test (OGTT) and euglycemic-hyperinsulinemic clamp to examine the presence of impaired insulin secretion and insulin resistance in isolated IFG, isolated IGT, and combined IFG/IGT.

RESEARCH DESIGN AND METHODS

The participants included 319 subjects of Mexican-American descent who were part of the San Antonio Veterans Administration Genetic Epidemiology Study. In the Veterans Administration Genetic Epidemiology Study, Mexican-American families with one diabetic and one nondiabetic parent and two siblings with type 2 diabetes were recruited through advertising within the medical center and in local newspapers. Subjects responding to the advertisement were screened with a 75-g OGTT. This study reports on 319 subjects with NGT, IFG, and IGT, 58 of whom also had a euglycemic insulin clamp study. Based on the OGTT, subjects were classified as having NGT (fasting glucose <5.6 mmol/l and 2-h glucose <7.8 mmol/l, $n = 117$), IGT (fasting glucose <5.6

TABLE 1
Anthropometric and metabolic characteristics of the different glucose-intolerant groups

	NGT	IFG	IGT	CGI	NGT vs. IFG	NGT vs. IGT	NGT vs. CGI	IFG vs. IGT
<i>n</i>	117	32	93	77				
Age (years)*	46 ± 11	49 ± 11	49 ± 11	51 ± 12	—	—	—	—
Sex (male/female)	37/80	17/15	23/70	21/56	0.02	—	—	0.003
BMI (kg/m ²)*	30.7 ± 6.9	32.6 ± 7	32.2 ± 5.6	34.7 ± 7.0	—	—	0.0007	—
Waist (cm)*	98.2 ± 20	100.5 ± 15.3	100.9 ± 13.6	106.5 ± 14.0	—	—	0.008	—
Total cholesterol (mg/dl)*	170 ± 38	193 ± 38	174 ± 37	177 ± 40	0.001	—	—	0.007
HDL cholesterol (mg/dl)	42.5 ± 12	40 ± 12	41 ± 11	40 ± 13	—	—	—	—
LDL cholesterol (mg/dl)	107 ± 31	124 ± 33	109 ± 31	110 ± 37	0.003	—	—	0.009
Triglycerides (mg/dl)*	102 ± 60	141 ± 86	118 ± 63	134 ± 86	0.002	0.04	0.002	0.05
Fasting glucose (mg/dl)†	89 ± 10	106 ± 4	92 ± 5	107 ± 6	<0.0001	0.007	<0.0001	<0.0001
2-h glucose (mg/dl)†	114 ± 18	119 ± 14	162 ± 15	165 ± 17	—	<0.0001	<0.0001	<0.0001
Fasting insulin (μU/ml)*	12 ± 9	16 ± 18	14 ± 9	17 ± 10	0.03	0.05	0.0003	—
2-h insulin (μU/ml)†	83 ± 55	71 ± 60	128 ± 91	132 ± 105	—	<0.0001	<0.0001	0.0007

Data are means ± SD. **P* < 0.01; †*P* < 0.0001 by ANOVA, indicating that the means of the four groups are significantly different.

mmol/l and 2-h glucose between 7.8 and 11.1 mmol/l, *n* = 93), IFG (fasting glucose between 5.6 and 7.0 mmol/l and 2-h glucose <7.8 mmol/l, *n* = 32), or combined glucose intolerance (CGI) (fasting glucose between 5.6 and 7 mmol/l and 2-h glucose between 7.8 and 11.1 mmol/l, *n* = 77), according to the American Diabetes Association criteria (8,27).

All subjects had normal liver, cardiopulmonary, and kidney function as determined by medical history, physical examination, screening blood tests, electrocardiogram, and urinalysis. No normal glucose-tolerant, IFG, or impaired glucose-tolerant subject was taking any medication known to affect glucose tolerance. Body weight was stable (±2 kg) for at least 3 months before study in all subjects. The study protocol was approved by the institutional review board of the University of Texas Health Science Center, San Antonio, and informed written consent was obtained from all subjects before their participation. All studies were performed at the general clinical research center of the University of Texas Health Science Center at 0800 following a 10- to 12-h overnight fast.

OGTT. Before the start of the OGTT, a small polyethylene catheter was placed into an antecubital vein and blood samples were collected at -30, -15, 0, 30, 60, 90, and 120 min for the measurement of plasma glucose and insulin concentrations. On the day of the OGTT, waist circumference was determined at the narrowest part of the torso (28).

Euglycemic insulin clamp. Before the start of the insulin clamp (29), a catheter was placed into an antecubital vein for the infusion of all test substances. A second catheter was inserted retrogradely into a vein on the dorsum of the hand, and the hand was placed into a thermoregulated box heated to 70°C. At 0800, all subjects received a primed (25 μCi)-continuous (0.25 μCi/min) infusion of 3-[³H]glucose (DuPont NEN Life Science Products, Boston, MA), which was continued for 2 h. After the basal tracer equilibration period, subjects received a primed-continuous insulin infusion at the rate of 240 pmol (40 mU) · min⁻¹ · m⁻² for 120 min. During the last 30 min of the basal equilibration period, plasma samples were taken at 5- to 10-min intervals for the determination of plasma glucose and insulin concentrations and tritiated glucose radioactivity. During the insulin infusion, plasma glucose concentration was measured every 5 min, and a variable infusion of 20% glucose was adjusted, based on the negative feedback principle, to maintain the plasma glucose concentration at each subject's fasting plasma glucose level with a coefficient of variation <5%. Plasma samples were collected every 15 min from 0 to 90 min and every 5-10 min from 90 to 120 min for the determination of plasma glucose and insulin concentrations and tritiated glucose specific activity.

Calculations. Following an overnight fast, steady-state conditions prevailed, and endogenous glucose production (EGP) was calculated as the tritiated glucose infusion rate (dpm/min) divided by the plasma tritiated glucose specific activity (dpm/mg). During the insulin clamp, non-steady-state conditions for tritiated glucose specific activity prevail, and the rate of glucose appearance (*R_a*) was calculated with Steele's equation (30). The rate of residual EGP during the insulin clamp was calculated by subtracting the rate of exogenous glucose infusion rate from the tracer-derived *R_a*. The insulin-stimulated rate of total glucose disposal (TGD) was calculated by adding the rate of residual EGP to the exogenous glucose infusion rate.

Insulin sensitivity indexes were also calculated from OGTT using the

Matsuda (31), HOMA-IR (32), ISIest (33), and oral glucose insulin sensitivity (OGIS) (34) indexes. The insulinogenic index or incremental area under the curve of insulin (ΔI[AUC]) divided by the incremental area under the curve of glucose (ΔG[AUC]) was calculated during the 0- to 30-min (early) and 0- to 120-min (total) time period of the OGTT. To evaluate β-cell function, the insulin secretion/sensitivity index (so called disposition index) was calculated as ΔI(AUC)/ΔG(AUC)/steady-state plasma insulin/TGD or ΔI(AUC)/ΔG(AUC) × Matsuda index. Incremental AUCs of plasma glucose and insulin during the OGTT were calculated according the trapezoid rule.

Analytical techniques. Plasma glucose was measured by the glucose oxidase reaction (Glucose Oxidase Analyzer; Beckman, Fullerton, CA). Plasma insulin concentration was measured by a radioimmunoassay (Linco Research, St. Louis, MO). Plasma 3-[³H]glucose radioactivity was measured in Somogyi precipitates.

Statistical analysis. Data are presented as the mean ± SE. Simple Pearson's correlation was used to assess the relationship between variables. For comparison between groups, Student's *t* test was used. To compare the mean of more than two groups, ANOVA was used. Statistical significance was considered at *P* < 0.05.

RESULTS

Table 1 presents the anthropometric and metabolic characteristics of the study groups. In general, subjects with IFG/IGT/CGI were slightly more obese than subjects with NGT. Subjects with IFG had a higher percentage of being male and higher total/LDL cholesterol concentrations. Subjects with high fasting plasma glucose concentrations (IFG and CGI) had significantly higher fasting plasma triglyceride and insulin concentrations than subjects with NGT.

Plasma glucose and insulin concentrations. Plasma glucose and insulin concentrations during the OGTT are displayed in Fig. 1. Compared with normal glucose-tolerant subjects, individuals with IGT had a small but significant increase in fasting plasma glucose concentration, but the 2-h plasma glucose and the incremental glucose AUC during the OGTT were markedly increased by 42 and 68%, respectively. Although the incremental insulin AUC in the impaired glucose-tolerant group was similar to that in the normal glucose-tolerant group, the time course of insulin response was very different (Fig. 1). Thus, the plasma insulin response rose progressively from 60 to 120 min in the impaired glucose-tolerant group, while it declined toward the baseline after 60 min in the normal glucose-tolerant group. By definition, subjects with IFG had significantly elevated fasting plasma glucose compared with




FIG. 1. Plasma glucose and insulin concentrations during the OGTT.

normal and impaired glucose-tolerant subjects, and their fasting plasma insulin concentration was higher than the value in both NGT and IGT. The incremental glucose AUC during the OGTT ($97 \pm 36 \text{ mg} \cdot \text{dl}^{-1} \cdot \text{h}^{-1}$) in the IFG group was intermediate between that of the normal ($74 \pm 34 \text{ mg} \cdot \text{dl}^{-1} \cdot \text{h}^{-1}$, $P < 0.0001$) and impaired ($124 \pm 31 \text{ mg} \cdot \text{dl}^{-1} \cdot \text{h}^{-1}$, $P < 0.0001$) glucose-tolerant groups. However, the 2-h plasma glucose concentration in the IFG group had returned to values observed in NGT (119 vs. 114 mg/dl, $P = \text{NS}$) and was markedly less than in the impaired glucose-

tolerant group (162 mg/dl). The incremental insulin AUC was significantly reduced in IFG compared with both IGT and NGT. Subjects with CGI had elevated plasma glucose and insulin concentrations, similar to those with IFG, and elevated incremental glucose and insulin AUC, similar to IGT. Thus, individuals with CGI shared the characteristics of both IFG and IGT.

Indexes of insulin resistance. Insulin resistance, calculated by HOMA-IR, was significantly higher in subjects with elevated fasting plasma glucose concentrations (IFG and CGI) compared with subjects with normal fasting glycemia (NGT and IGT). However, insulin sensitivity, calculated by the Matsuda, IS_{Iest}, and OGIS indexes, were significantly reduced in the three glucose-intolerant groups (IFG, IGT, and CGI) compared with subjects with NGT (Table 2). The three indexes were virtually identical in IFG and impaired glucose-tolerant groups.

Direct measurement of insulin sensitivity. A total of 58 subjects received a euglycemic-hyperinsulinemic clamp: 29 subjects with NGT, 10 subjects with IFG, 9 subjects with IGT, and 10 subjects with CGI. Insulin-stimulated total-body glucose disposal was similar in subjects with NGT and IFG, and it was reduced by 42 and 48%, respectively, in subjects with IGT and CGI compared with NGT (Table 2, Fig. 2). The basal hepatic insulin resistance index (hepatic glucose production [HGP] \times fasting plasma insulin [FPI]) was significantly increased by 35–40% in IFG and CGI compared with NGT. There was a small, but significant (11%), increase in the hepatic insulin resistance index in IGT (Fig. 2).

Correlation between OGTT- and clamp-derived insulin sensitivity indexes. Table 3 presents the simple Pearson's correlations between OGTT-derived insulin sensitivity indexes and TGD measured with the insulin clamp and basal hepatic insulin resistance index (HGP \times FPI). HOMA-IR correlated more strongly with the basal hepatic insulin resistance index than with TGD, while the Matsuda, Stumvoll, and OGIS indexes correlated more strongly with TGD than with the basal hepatic insulin resistance index.

Insulin secretion. Insulin secretion during the 120-min OGTT, measured by $\Delta\text{I}(\text{AUC})/\Delta\text{G}(\text{AUC})$, was reduced sim-

TABLE 2
Indexes of insulin sensitivity and insulin secretion in the different glucose-intolerant groups

	NGT	IFG	IGT	CGI	NGT vs. IFG	NGT vs. IGT	NGT vs. CGI	IFG vs. IGT
$\Delta\text{G}(\text{AUC})$ ($\text{mg} \cdot \text{dl}^{-1} \cdot \text{h}^{-1}$)*	74 \pm 34	97 \pm 36	124 \pm 31	128 \pm 35	0.0008	<0.0001	<0.0001	<0.0001
$\Delta\text{I}(\text{AUC})$ ($\mu\text{U} \cdot \text{ml}^{-1} \cdot \text{h}^{-1}$)*	146 \pm 96	118 \pm 80	155 \pm 96	175 \pm 162	0.06	—	0.07	0.02
$\Delta\text{I}(\text{AUC})/\Delta\text{G}(\text{AUC})$ *†	2.4 \pm 1.9	1.3 \pm 0.9	1.3 \pm 0.9	1.4 \pm 1.3	0.0008	<0.0001	<0.0001	—
$\text{I}_{0-30}/\text{G}_{0-30}$ ($\mu\text{U}/\text{ml}$ per mg/dl)*	1.8 \pm 1.4	0.9 \pm 0.5	1.33 \pm 1.0	0.9 \pm 0.7	<0.0001	0.002	<0.0001	0.007
HOMA-IR*‡	2.7 \pm 2.2	4.3 \pm 4.9	3.2 \pm 2.1	4.6 \pm 3.3	0.004	0.09	<0.0001	0.03
Matsuda index*	4.2 \pm 2.9	3.3 \pm 1.9	3.2 \pm 2.2	2.4 \pm 2.5	0.0008	<0.0001	<0.0001	—
IS _{Iest} †	0.13 \pm 0.05	0.11 \pm 0.04	0.11 \pm 0.05	0.10 \pm 0.05	<0.05	<0.05	<0.001	—
OGIS*	393 \pm 62	364 \pm 56	371 \pm 66	309 \pm 59	0.01	0.01	<0.0001	—
Basal EGP ($\text{mg} \cdot \text{kg}^{-1} \cdot \text{min}^{-1}$)*	1.73 \pm 0.4	1.82 \pm 0.34	1.66 \pm 0.18	1.65 \pm 0.21	—	—	—	—
Basal EGP \times FPI*	19.4 \pm 4.3	30.2 \pm 6.4	24.1 \pm 3.1	29.1 \pm 5.2	0.02	—	0.01	—
TGD/SSPI \times 100*	6.6 \pm 3.1	8.0 \pm 4.3	3.8 \pm 2.2	3.4 \pm 1.2	—	0.03	0.01	0.008
$(\Delta\text{I}_{0-30}/\Delta\text{G}_{0-30}) \times$ Matsuda index*	36 \pm 22	15 \pm 9	18 \pm 9	12 \pm 6	<0.0001	<0.0001	<0.0001	0.04
$(\Delta\text{I}_{0-30}/\Delta\text{G}_{0-30})$ (TGD/SSPI) \times 100*	9.9 \pm 5.3	7.7 \pm 4.4	3.7 \pm 2.6	4.7 \pm 2.2	0.1	<0.0001	0.0007	0.006
$\Delta\text{I}(\text{AUC})/\Delta\text{G}(\text{AUC}) \times$ (TGD/SSPI)*	0.93 \pm 0.7	0.73 \pm 0.5	0.28 \pm 0.2	0.47 \pm 0.2	—	0.004	0.03	0.02

Data are means \pm SD. The Matsuda index of insulin sensitivity was calculated according to (31). The IS_{Iest} of insulin sensitivity was calculated according to (33). The OGIS index of insulin sensitivity was calculated according to (34). * $P < 0.01$; † $P < 0.0001$ by ANOVA, indicating that the means of the four groups are significantly different. $\Delta\text{G}(\text{AUC})$, incremental AUC of glucose during the OGTT; $\Delta\text{I}(\text{AUC})$, incremental AUC of insulin during the OGTT; SSPI, steady-state plasma insulin during the last 30 min of the insulin clamp.




FIG. 2. Total-body (primarily reflects muscle) insulin sensitivity (A) measured with the insulin clamp and the hepatic insulin sensitivity index (B) measured with tritiated glucose in the different glucose-intolerant groups. SSPI, steady-state plasma insulin concentration during the last 30 min of the insulin clamp.

ilarly by ~45% in all three glucose-intolerant groups. The early insulin response ($\Delta I_{0-30}/\Delta G_{0-30}$) was more severely impaired in the IFG and CGI groups compared with IGT (both $P < 0.001$ vs. IGT). In the subgroup of subjects who received a euglycemic insulin clamp, both $\Delta I_{0-30}/\Delta G_{0-30}$ and $\Delta I_{0-120}/\Delta G_{0-120}$, related to insulin-mediated TGD, were slightly but not significantly reduced in the IFG versus the normal glucose-tolerant group; both the 0- to 30-min and 0- to 120-min insulinogenic indices were significantly reduced in the impaired glucose-tolerant and CGI groups compared with the normal glucose-tolerant and IGF groups.

DISCUSSION

The present results demonstrate that subjects with IGT and IFG have distinct pathophysiological disturbances. During the euglycemic-hyperinsulinemic clamp, TGD in

TABLE 3

Pearson's correlation coefficients between OGTT-derived insulin sensitivity indexes and liver and muscle insulin sensitivity measured during the clamp

	Correlation with TGD/SSPI	Correlation with EGP × FPI
HOMA-IR	-0.564 ($P < 0.0001$)	0.640 ($P < 0.0001$)
Matsuda index	0.688 ($P < 0.0001$)	-0.4897 ($P = 0.0002$)
ISIest	0.674 ($P < 0.0001$)	-0.4903 ($P = 0.0002$)
OGIS	0.566 ($P < 0.0001$)	-0.3143 ($P = 0.02$)

HOMA-IR index was calculated from fasting plasma glucose and insulin concentrations during the OGTT. The hepatic insulin sensitivity index was calculated using the fasting plasma insulin concentration measured on the day of the insulin clamp. SSPI, steady-state plasma insulin concentration during the last 30 min of the insulin clamp.

IFG subjects was similar to that in normal glucose-tolerant subjects, while insulin-mediated glucose disposal was markedly reduced in subjects with IGT and CGI. Since >80–90% of glucose disposal during the euglycemic-hyperinsulinemic clamp occurs in skeletal muscle (29,35), subjects with IGT and CGI are characterized by moderate-to-severe muscle insulin resistance. In contrast, muscle insulin sensitivity was normal in subjects with IFG. When HOMA-IR was used to derive an index of insulin resistance, IFG subjects were found to be markedly insulin resistant compared with subjects with NGT, while impaired glucose-tolerant subjects had minimally (not significantly) reduced insulin sensitivity. Using HOMA-IR, CGI subjects were as insulin resistant as IFG individuals. This apparent discrepancy between HOMA-IR and the insulin clamp-derived measurement of insulin resistance does not reflect methodological inconsistencies but rather the different underlying physiological processes that are being quantitated. The HOMA-IR index is derived from the product of the fasting plasma glucose and insulin concentrations (32). Since HGP is the primary determinant of the fasting plasma glucose concentration (36), and the fasting plasma insulin concentration is the primary regulator of HGP (37), the product of fasting plasma glucose and FPI primarily reflects hepatic insulin resistance. This is confirmed in the subgroup of subjects who received tritiated glucose to measure HGP. In this subgroup of subjects, HOMA-IR correlated more strongly with HGP × FPI than with TGD. In the IFG group, the hepatic insulin resistance index (HGP × FPI) was increased, while in IGT it was only minimally elevated. We have previously shown that there is a 70% concordance between muscle insulin resistance and liver insulin resistance in the same subject (38). Thus, we interpret our results to indicate that individuals with IFG are primarily characterized by hepatic insulin resistance, while subjects with IGT mainly have muscle insulin resistance. These conclusions are consistent with previously published results. Festa et al. (24) and Weyer et al. (23) have reported that subjects with isolated IGT had a significant reduction in insulin sensitivity, as measured with an intravenous glucose tolerance test and insulin clamp. On the other hand, the product of EGP × FPI was markedly increased in subjects with IFG (23). Fasting hyperinsulinemia has been observed in subjects with IFG in all (14–17,19,23–26) but one (22) study. The higher product of fasting plasma glucose × FPI in individuals with IFG indicates the presence of hepatic insulin resistance.

Individuals with CGI manifested marked fasting hyperinsulinemia and had both reduced TGD during the insulin clamp and a high HOMA-IR. The former reflects muscle insulin resistance, while the later (HOMA-IR) is indicative of hepatic insulin resistance. Thus, subjects with CGI had both muscle and liver insulin resistance, and both defects were quite severe. The combination of severe liver and muscle insulin resistance in subjects with CGI may explain their higher risk (twofold greater than IGT and IFG) for progression to type 2 diabetes in prospective epidemiological studies (3–7). The Matsuda index of insulin sensitivity (31) contains the fasting plasma glucose × FPI (index of hepatic insulin resistance) and the mean plasma glucose multiplied by the mean plasma insulin during the OGTT (index of muscle insulin resistance). Therefore, it is not surprising that it more strongly correlates with TGD than HOMA-IR, and it was reduced to a significantly greater extent in CGI compared with both IGT and IFG. Similarly, ISIest and OGIS indexes, which are also derived from

plasma glucose and insulin concentrations during the OGTT, displayed a greater correlation with TGD than with liver insulin resistance (HOMA-IR).

The early-phase (0–30 min) insulinogenic index was diminished in all three glucose-intolerant groups. However, when expressed as $\Delta I_{0-30}/\Delta G_{0-30}/IR$, subjects with IGT and CGI had a greater reduction in insulin secretion than subjects with IFG. Similarly, $\Delta I_{0-120}/\Delta G_{0-120}/IR$ was more severely reduced in IGT and CGI compared with IFG. Previous studies, which have measured insulin secretion with the hyperglycemic clamp (17,20) and intravenous glucose tolerance tests (23,24), consistently reported a 25–50% reduction in first- and second-phase insulin secretion in subjects with IGT compared with NGT. Since, in all of the above studies (17,20,23,24), subjects with IGT were insulin resistant compared with NGT, expression of first- and second-phase insulin secretion in relation to insulin resistance would have yielded a more profound reduction in insulin secretion in subjects with IGT, as we have previously reported (21). Unfortunately, no study has directly measured first- and second-phase insulin secretion with the hyperglycemic clamp and compared the results in subjects with IFG and IGT. Several studies have used the intravenous glucose tolerance test to measure the acute insulin response in IFG subjects (23,24) and observed a significant reduction in the absolute magnitude of acute insulin response compared with subjects with NGT. However, the insulin secretory response was not related to the severity of insulin resistance.

The metabolic characteristics described above (summarized in Table 2) help to explain the plasma glucose profile following ingestion of glucose load or mixed meal in individuals with IGT, IFG, and CGI. In subjects with IGT, the combination of deficient insulin secretion plus muscle insulin resistance results in less efficient disposal of the glucose load during the OGTT. As a result, the plasma glucose concentration continues to increase after 60 min and remains elevated at 120 min (Fig. 1). This is in contrast to normal glucose-tolerant subjects in whom the plasma glucose concentration peaks at 30 min and returns to the mean basal value at 120 min. Subjects with IFG start with a high fasting plasma glucose level (due to hepatic insulin resistance), but the incremental rise in plasma glucose concentration at 30–60 min is only slightly greater than NGT (Fig. 1), and at 120 min the plasma glucose concentration returns to a value similar to that in NGT. Consequently, the increment in plasma glucose concentration above baseline from 0 to 120 min was only slightly greater than in the normal glucose-tolerant group. This is explained by normal muscle insulin sensitivity (measured with the insulin clamp), which, even in the face of a modest defect in insulin secretion, is able to maintain a near-normal incremental plasma glucose response during the OGTT. Individuals with CGI start with a high fasting plasma glucose concentration because of hepatic insulin resistance and have the greatest rise in plasma glucose concentration during the OGTT because of muscle (and hepatic) insulin resistance and impaired insulin secretion.

In summary, a clearer understanding of the pathophysiological abnormalities that characterize varying glucose-intolerant groups provides insights into the development of interventions to slow/halt the progression to type 2 diabetes. Subjects with IFG, who predominantly manifest liver insulin resistance, are most likely to benefit from agents that improve hepatic insulin sensitivity, such as metformin, while subjects with IGT, who predominantly

have muscle insulin resistance combined with severely impaired insulin secretion, are more likely to respond to agents that improve skeletal muscle insulin resistance, such as a peroxisome proliferator-activated receptor- γ agonist, in combination with an insulin secretagogue such as a glucagon-like peptide-1 derivative.

ACKNOWLEDGMENTS

This work was supported by National Institutes of Health Grant DK24092, a Veterans Administration Merit Award, a Veterans Administration Epidemiologic grant, and a General Clinical Research grant.

We thank our nurses, James King, John Kincaid, Rose Kaminski-Graham, and Norma Diaz, for assistance in performing the OGTT and insulin clamp studies and for their excellent care of the patients throughout the study. The invaluable assistance of Lih-Lan Hu in preparing the database is highly appreciated. Elva Chapa and Lorrie Albarado provided expert secretarial assistance in manuscript preparation.

REFERENCES

1. WHO Study Group: *Diabetes Mellitus*. Geneva, World Health Org., 1985 (Tech. Rep. Ser., no. 727)
2. DeFronzo RA: Pathogenesis of type 2 diabetes mellitus. *Med Clin North Am* 88:787–835, 2004
3. Unwin N, Shaw J, Zimmet P, Alberti KGMM: Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. *Diabet Med* 19:708–723, 2002
4. Shaw J, Zimmet P, de Courten M, Dowse G, Chitson P, Gareeboo H, Hemraj F, Fareed D, Tuomilehto J, Alberti K: Impaired fasting glucose or impaired glucose tolerance: what best predicts future diabetes in Mauritius? *Diabetes Care* 22:399–402, 1999
5. Gabir MM, Hanson R, Dabelea D, Imperatore G, Roumain J, Bennett P, Knowler W: Plasma glucose and prediction of microvascular disease and mortality: evaluation of 1997 American Diabetes Association and 1999 World Health Organization criteria for diagnosis of diabetes. *Diabetes Care* 23:1113–1118, 2000
6. de Vegt F, Dekker JM, Stehouwer CD, Nijpels G, Bouter LM, Heine RJ: The 1997 American Diabetes Association criteria versus the 1985 World Health Organization criteria for the diagnosis of abnormal glucose tolerance: poor agreement in the Hoorn Study. *Diabetes Care* 21:1686–1690, 1998
7. Eschwege E, Charles MA, Simon D, Thibault N, Balkau B, the Paris Prospective Study: Reproducibility of the diagnosis of diabetes over a 30-month follow-up: the Paris Prospective Study. *Diabetes Care* 24:1941–1944, 2001
8. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care* 20:1183–1197, 1997
9. Dunstan D, Zimmet P, Welborn T, de Courten M, Cameron A, Sicree R, Dwyer T, Colagiuri S, Jolley D, Knuiaman M, Atkins R, Shaw J: The rising prevalence of diabetes mellitus and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study. *Diabetes Care* 25:829–834, 2002
10. Larsson H, Berglund G, Lindgarde F, Ahren B: Comparison of ADA and WHO criteria for diagnosis of diabetes and glucose intolerance. *Diabetologia* 41:1124–1125, 1998
11. Harris MI, Eastman RC, Cowie CC, Flegal KM, Eberhardt MS: Comparison of diabetes diagnostic categories in the U.S. population according to the 1997 American Diabetes Association and 1980–1985 World Health Organization diagnostic criteria. *Diabetes Care* 20:1859–1862, 1997
12. Ko GT, Chan JC, Woo J, Cockram CS: Use of the 1997 American Diabetes Association diagnostic criteria for diabetes in a Hong Kong Chinese population. *Diabetes Care* 21:2094–2097, 1998
13. The DECODE Study Group: Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. *Lancet* 354:617–621, 1999
14. Tripathy D, Carlsson M, Almgren P, Isomaa B, Taskinen MR, Tuomi T, Groop LC: Insulin secretion and insulin sensitivity in relation to glucose tolerance: lessons from the Botnia Study. *Diabetes* 49:975–980, 2000
15. Guerrero-Romero F, Rodriguez-Moran M: Impaired glucose tolerance is a

- more advanced stage of alteration in the glucose metabolism than impaired fasting glucose. *J Diab Comp* 15:34–37, 2001
16. Weyer C, Bogardus C, Mott DM, Pratley RE: The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. *J Clin Invest* 104:787–794, 1999
 17. Haeften TWV, Pimenta W, Mitrakou A, Korytkowski M, Jenssen T, Yki-Jarvinen H, Gerich JE: Disturbance in β cell function in impaired fasting glycemia. *Diabetes* 51 (Suppl. 1):S265–S270, 2002
 18. Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Pettiti M, Mari A, DeFronzo RA: Predominant role of reduced beta-cell sensitivity to glucose over insulin sensitivity in impaired glucose tolerance. *Diabetologia* 46: 1211–1219, 2003
 19. Hanefeld M, Koehler C, Fuecker K, Henkel E, Schaper F, Temelkova-Kurktschiev T: Insulin secretion and insulin sensitivity pattern is different in isolated impaired glucose tolerance and impaired fasting glucose, the risk factor in Impaired Glucose Tolerance for Atherosclerosis and Diabetes study. *Diabetes Care* 26:868–874, 2003
 20. Pimenta WP, Santos ML, Cruz NS, Aragon FF, Padovani CR, Gerich JE: Brazilian individuals with impaired glucose tolerance are characterized by impaired insulin secretion. *Diabetes Metab* 28:468–476, 2002
 21. Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, DeFronzo RA, the San Antonio Metabolism Study: Beta-cell dysfunction and glucose intolerance: results from the San Antonio Metabolism (SAM) study. *Diabetologia* 47:31–39, 2003
 22. Schianca GPC, Rossi A, Sainaghi PP, Maduli E, Bartoli E: The significance of impaired fasting glucose versus impaired glucose tolerance: importance of insulin secretion and resistance. *Diabetes Care* 26:1333–1337, 2003
 23. Weyer C, Bogardus C, Pratley R: Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance. *Diabetes* 48:2197–2203, 1999
 24. Festa A, D'Agostino R, Hanley A, Karter AJ, Saad MF, Haffner SM: Differences in insulin resistance in nondiabetic subjects with isolated impaired glucose tolerance or isolated impaired fasting glucose. *Diabetes* 53:1549–1555, 2004
 25. Davies MJ, Raymond NT, Day JL, Hales CN, Burden AC: Impaired glucose tolerance and fasting hyperglycaemia have different characteristics. *Diabet Med* 17:433–440, 2000
 26. Conget I, Fernandez Real JM, Costa A, Casamitjana R, Ricart W: Insulin secretion and insulin sensitivity in relation to glucose tolerance in a group of subjects at a high risk for type 2 diabetes mellitus. *Med Clin* 116:491–492, 2001
 27. Genuth S, Alberti KG, Bennett P, Buse J, DeFronzo R, Kahn R, Kitzmiller J, Knowler WC, Lebovitz H, Lernmark A, Nathan D, Palmer J, Rizza R, Saudek C, Shaw J, Steffes M, Stern M, Tuomilehto J, Zimmet P, the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Follow-up report on the diagnosis of diabetes mellitus. *Diabetes Care* 26:3160–3167, 2003
 28. Bonora E, Del Prato S, Bonadonna RC, Gulli G, Solini A, Shank ML, Ghiatas AA, Lancaster JL, Kilcoyne RF, Alyassin AM, DeFronzo RA: Total body fat content and fat topography are associated differently with in vivo glucose metabolism in nonobese and obese nondiabetic women. *Diabetes* 41:1151–1159, 1992
 29. DeFronzo RA, Tobin JD, Andres R: Glucose clamp technique: a method for quantifying insulin secretion and resistance. *Am J Physiol* 237:E214–E223, 1979
 30. Altszuler N, De bodo RC, Steele R, Wall JS: Measurement of size and turnover rate of body glucose pool by the isotope dilution method. *Am J Physiol* 187:15–24, 1956
 31. Matsuda M, DeFronzo RA: Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic glucose clamp. *Diabetes Care* 22:1462–1470, 1999
 32. Matthews D, Hosker J, Rudenski A, Naylor B, Treacher D, Turner R: Homeostasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia* 28:412–419, 1985
 33. Stumvoll M, Mitrakou A, Pimenta W, Jenssen T, Yki-Jarvinen H, Van Haeften T, Renn W, Gerich J: Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. *Diabetes Care* 23:295–301, 2000
 34. Mari A, Pacini G, Murphy E, Ludvik B, Nolan JJ: A model-based method for assessing insulin sensitivity from the oral glucose tolerance test. *Diabetes Care* 24:539–548, 2001
 35. Shulman GI, Rothman DL, Jue T, Stein P, DeFronzo RA, Shulman RG: Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin dependent diabetes by ^{13}C nuclear magnetic resonance spectroscopy. *N Engl J Med* 322:223–228, 1990
 36. DeFronzo RA, Ferrannini E, Simonson DC: Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. *Metabolism* 38:387–395, 1989
 37. Sindelar DK, Chu CA, Venson P, Donahue EP, Neal DW, Cherrington AD: Basal hepatic glucose production is regulated by the portal vein insulin concentration. *Diabetes* 47:523–529, 1998
 38. Matsuda M, DeFronzo RA: Relationship between insulin sensitivity in adipose tissue, liver, muscle, and components of the insulin resistance syndrome (Abstract). *Diabetes* 46 (Suppl. 1):68A, 1997